Immuron Limited
ASX: IMC.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven George Lydeamore
- Employees
- 7
- Headquarters
- Carlton, Australia
- IPO year
- 1999
- Market cap
- A$7.5M
- Website
- https://www.immuron.com.au
Loading IMC…
Loading profile data…Frequently asked questions about IMC
What does Immuron Limited (IMC.AX) do?
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to...
Where does IMC.AX trade?
Immuron Limited (IMC.AX) trades on the Australian Securities Exchange.
What sector is IMC.AX in?
Immuron Limited (IMC.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immuron Limited?
Steven George Lydeamore is the chief executive officer of Immuron Limited (IMC.AX).
Where is Immuron Limited headquartered?
Immuron Limited is headquartered in Australia.
Does IMC.AX pay a dividend?
Immuron Limited (IMC.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMC.AX go public?
Immuron Limited (IMC.AX) completed its initial public offering in 1999.